Skip to main content

Table 1 Clinical characteristics of neonates with and without persistent candidemia

From: Persistent candidemia in very low birth weight neonates: risk factors and clinical significance

Variable

Persistent candidemia

P value

Odds ratio (OR) (95% CI)

Yes mean (95% CI) or n (%)

No mean (95% CI) or n (%)

Demographics

 Gestational age (wks)

29.6 (27.3, 31.9)

29.7 (28.1, 31.2)

0.766

 

 Birth weight (g)

1097.8 (866.4,1309.2)

1229.0 (1051.1,1046.9)

0.029

 

 Male gender, n (%)

12 (42.9)

5 (25.0)

0.207

0.44 (0.13–1.57)

 Admission age

1.3 (0.4, 2.2)

1.8 (2.4, 6.0)

0.611

 

Risk factors

 Necrotizing enterocolitis

9 (32.1)

1 (5.0)

0.046

9.0 (1.04–78.17)

 Neurodevelopmental impairment

6 (21.4)

6 (30.0)

0.501

0.64 (0.17–2.37)

 Vaginal delivery

13 (46.4)

7 (35.0)

0.430

1.61 (0.49–5.25)

 Fetal membrane rupture (h)

46.4 (25.1, 117.7)

18.8 (37.5, 75.1)

0.143

 

 Congentital diseases

15 (53.6)

10 (50.0)

0.867

1.15 (0.37–3.64)

 Abdominal surgery

3 (10.7)

0 (0.0)

 Mechanical ventilation

24 (85.7)

10 (50.0)

0.011

6.00 (1.52–23.70)

 Central venous catheter

15 (59.6)

13 (65.0)

0.430

0.62 (0.19–2.03)

 Intubation

20 (71.4)

3 (15.0)

0.000

14.17 (3.24–61.99)

 Total parenteral nutrition

26 (92.9)

19 (95.0)

0.764

0.68 (0.06–8.11)

 Hospitalization duration (d)

58.8 (33.8, 93.8)

49.3 (32.4, 66.2)

0.147

 

 3rdcephalosporins use

16 (59.3)

13 (65.0)

0.689

0.78 (0.24–2.59)

 Carbapenems use

26 (92.9)

16 (80.0)

0.201

3.25 (0.53–19.82)

 Vancomycin use

7 (25.0)

2 (10.0)

0.203

3.00 (0.55–16.31)

 Multiple antibiotic use

18 (64.3)

13 (65.0)

0.959

0.97 (0.29–3.22)

 Antibiotic therapeutic duration (d)

44.5 (24.3, 64.7)

31.1 (16.6, 55.6)

0.015

 

 Non-C.albicans

21 (75.0)

8 (40.0)

0.017

4.50 (1.31–15.52)

 Prophylaxis antifungal therapy

25 (89.3)

16 (80.0)

0.375

2.08 (0.41–10.56)

 Antifungal therapeutic duration (d)

11.3 (4.6, 18.0)

9.2 (4.6, 14.4)

0.243

 

Outcome

 Death

4 (14.3)

1 (5.0)

0.320

3.17 (10.33–30.73)